Table 1.
Patient characteristics
| (n = 190) | |
|---|---|
| Age, y (median, IQR) | 45 (39–49) |
| Sex (male/female) | 158/32 (83 %/17 %) |
| HIV risk factor | 74 (39 %) |
| IDU | 61 (32 %) |
| MSM | 49 (26 %) |
| Heterosexual | 6 (3 %) |
| Other/unknown | |
| AIDS | 55 (29 %) |
| HCV | 61 (32) |
| HBV | 8 (4 %) |
| Current ART | 182 (96 %) |
| CD4+ T cell count, cells/μL (median, IQR) | 528 (351–740) |
| CD4+ T cell count, <200 cells/μL | 19 (10 %) |
| HIV RNA, <40 copies/mL | 153 (80 %) |
| Current use of TMP-SMX | 15 (8 %) |
| Origin | Delete |
| Spain | 161 (85%) |
| Europe | 1 (0.5%) |
| South America | 19 (10%) |
| North Africa | 4 (2%) |
| Sub-Saharan Africa | 4 (2%) |
| Asia | 1 (0.5%) |
| Risk factors for HA-MRSA acquisition | |
| Antibiotic use in prior 12 months | 70 (37 %) |
| Hospitalization in prior 12 months | 32 (17 %) |
| Intravenous catheter use in prior 12 months | 40 (21 %) |
| Surgical intervention in prior 12 months | 19 (10 %) |
| Frequent visits (≥1 per week) to long-term care facilities | 17 (9 %) |
| Multiple sexual partners in prior 12 months | 17 (9 %) |
| History of sexually transmitted infection | 17 (9 %) |
| Previous incarceration | 29 (15 %) |
Data are shown as number (%) of patients unless otherwise indicated.
IDU, injecting drug user; IQR, interquartile range; HBV, hepatitis B virus; HCV, hepatitis C virus; MSM: men who have sex with men; TMP-SMX: trimethoprim-sulfamethoxazole